Virbac : Driven by very solid performance in all areas and a very dynamic market, we are raising our outlook for 2021
July 06, 2021 at 04:40 am EDT
Share
Driven by very solid performance in all areas and a very dynamic market, we are raising our outlook for 2021
2021 Outlook
The animal health sector has shown excellent dynamism in the first months of 2021. A number of indicators, such as visits to veterinarians, companion animal adoptions, as well as the rebound observed in the food producing animal segment are very positively oriented and should continue to support the growth of the animal health market in 2021. In addition, we continue to execute our strategic plan, and deliver very strong performances in all areas where we operate thanks to the commitment of our teams.
In this context, we are raising our annual outlook. We currently anticipate revenue growth at constant rates and scope between 10% and 14% (i.e. between 7% and 11% at constant rates and real perimeter), as well as a ratio of 'current operating profit, before depreciation of assets arising from acquisitions' over 'revenue' which should be around 15% at constant exchange rates. Furthermore, we anticipate an unfavorable impact of exchange rates on revenue of approximately €13 million linked to the devaluation of currencies.
For the coming months, the health crisis could still create uncertainty and impact our business. As explained previously, we have implemented a set of measures and daily monitoring to prevent and limit potential impacts (crisis management system, supply chain and inventory management policies, readjustment of the targets of our safety stocks, business continuity plans for industrial sites, sourcing diversification policies and strengthening relationships with our strategic suppliers, etc.). In addition, our global presence in terms of geographic areas and species, our highly diversified product portfolio, our different distribution channels, the very strong responsiveness and adaptability of our teams through our organizational model, as well as the robustness of our financial situation are assets that will enable us to face the consequences of this pandemic. However, we remain vigilant to the evolution of the pandemic in the coming months, and are fully mobilized to manage it.
GO BACK
Attachments
Original document
Permalink
Disclaimer
Virbac SA published this content on 05 July 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 06 July 2021 08:39:03 UTC.
Virbac specializes in the research, production and marketing of veterinary medicines. The activity is organized around 2 product families:
- pet medications: pest control drugs, vaccines, antibiotics, anesthetics, anti-inflammatory drugs, mouth/dental care products, ophthalmologic and dermatological products intended for dogs, cats, horses, birds, rodents, etc. The group also offers foods and electronic identification chips;
- livestock medications: pest control drugs and antibiotics intended for cattle, sheep, pigs, poultry, etc.
Net sales are distributed geographically as follows: France (15.8%), Europe (24.9%), Asia (17.5%), Latin America (16.2%), North America (13.3%), Pacific (9.7%), Africa and Middle East (2.6%).